UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation or organization) |
(Commission File Number) |
(I.R.S. Employer Identification Number) |
(Address of principal executive offices and zip code) |
||
( |
||
(Registrant's telephone number, including area code) |
||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act: |
||||
Title of each class |
|
Trading Symbol |
|
Name of each exchange on which registered |
|
|
|||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 12b-2 of the Exchange Act.
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On November 6, 2024, the Board of Directors of Standard BioTools Inc. (the “Company”) appointed Alex Kim, who has been serving as the Company’s Interim Chief Financial Officer since September 1, 2024, as the Company’s fulltime Chief Financial Officer, effective as of November 11, 2024 (the “Effective Date”). In this role, Mr. Kim will continue to serve as the Company’s Principal Financial Officer and Principal Accounting Officer.
In connection with his appointment as Chief Financial Officer, effective as of the Effective Date, Mr. Kim will no longer serve as the Company’s Chief Operating Officer, and the Company will vacate the position of Chief Operating Officer.
Biographical information for Mr. Kim can be found under the caption “Management and Corporate Governance – Executive Officers” in the Company’s Definitive Proxy Statement on Schedule 14A, filed with the SEC on May 21, 2024, and is incorporated herein by reference. There are no family relationships between Mr. Kim and any director or executive officer of the Company that are required to be disclosed pursuant to Item 401(d) of Regulation S-K, and there are no arrangements or understandings between Mr. Kim and any other persons pursuant to which Mr. Kim was appointed to serve as Chief Financial Officer of the Company. There are no transactions between Mr. Kim and the Company that would be reportable under Item 404(a) of Regulation S-K. Mr. Kim will not receive any additional compensation for serving as Chief Financial Officer.
A copy of the press release announcing Mr. Kim’s appointment as Chief Financial Officer is attached hereto as Exhibit 99.1 and incorporated herein by reference.
Item 9.01 - Financial Statements and Exhibits
(d) Exhibits
Exhibit No. |
|
Description |
99.1 |
|
Press release issued by Standard BioTools Inc., dated November 7, 2024. |
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Date: |
|
November 7, 2024 |
|
|
|
|
|
|
|
|
|
STANDARD BIOTOOLS INC. |
||
|
|
|
|
|
By: |
|
/s/ Michael Egholm, Ph.D. |
|
Name: |
|
Michael Egholm, Ph.D. |
|
Title: |
|
President and Chief Executive Officer |
|
|
|
|
|
|
|
|
Exhibit 99.1
Standard BioTools Appoints Alex Kim as Chief Financial Officer
SOUTH SAN FRANCISCO, Calif., November 7, 2024 -- Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced the appointment of Alex Kim as Chief Financial Officer, effective November 11, 2024. Kim, a co-founder and most recently Chief Operating Officer of Standard BioTools, brings nearly 30 years of financial and operations experience in the healthcare and life sciences industries to the role and will oversee Standard BioTools’ finance organization.
Michael Egholm, President and Chief Executive Officer of Standard BioTools, said, “I am thrilled to announce Alex as our next CFO. Having co-founded Standard BioTools with me, Alex’s deep understanding of our business make him the clear choice for the role and he will continue to be a key architect in the design and implementation of our strategic and financial plans moving forward.”
Prior to joining Standard BioTools, Kim was President of Milliken’s Healthcare Division, initially joining the company in 2015 as Executive Vice President of Corporate Strategy and Corporate Development. From 2012 to 2015, he was Senior Vice President of Strategy and Business Development at Pall Corporation and prior to that from 2002 to 2012, Kim worked at Danaher Corporation in a variety of roles across general management, M&A and business development. Over his career, Kim has completed over 40 transactions, largely focused on healthcare, medical technology and life sciences. He also brings strong operational execution experience, having been intimately involved in integrations and most recently with full operational leadership of a business.
Kim said, “I am delighted to assume the CFO position and continue working alongside Michael and our talented team as we execute the Standard BioTools vision. We have strong momentum and we are moving forward with steadfast focus on operational excellence to achieve our financial targets and long-term growth objectives.”
In connection with this appointment, Jonathan Mickelsen, Standard BioTools’ Vice President and Corporate Controller, has been appointed as the Company’s Vice President & Chief Accounting Officer.
About Standard BioTools Inc.
Standard BioTools Inc. (Nasdaq:LAB), the parent company of SomaLogic Inc. and previously known as Fluidigm Corporation, has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more at standardbio.com or connect with us on X, Facebook®, LinkedIn, and YouTube™.
For Research Use Only. Not for use in diagnostic procedures.
Limited Use Label License and other terms may apply: standardbio.com/legal/salesterms. Patent and License Information: standardbio.com/legal/notices.
Trademarks: standardbio.com/legal/trademarks. Any other trademarks are the sole property of their respective owners. ©2024 Standard BioTools Inc. (f.k.a. Fluidigm Corporation). All rights reserved.
Investor Contact
David Holmes
Gilmartin Group LLC
(332) 330-1031
ir@standardbio.com